We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Prognostic Biomarker Detects Acute Kidney Injury

By LabMedica International staff writers
Posted on 08 Aug 2011
A renal injury biomarker in urine or blood detects early subclinical acute kidney injury (AKI) and its adverse outcomes in critically ill patients. More...


Early testing for the biomarker, neutrophil gelatinase-associated lipocalin (NGAL) may therefore allow earlier conventional medical interventions or introduction of novel therapies to improve the prognosis of AKI.

In a retrospective study, involving 13 international medical organizations, data from 2,322 critically ill adult and pediatric patients was pooled. These same patients did not have diagnostic increases in serum creatinine, which is considered the current gold standard for detecting AKI. The critically ill patients whose data was analyzed primarily had Type 1 cardiorenal syndrome, a common condition in which heart dysfunction causes kidney injury.

The scientists recorded that 40% of the patients showed unexpected early increases in urine or blood NGAL levels, but no increases in serum creatinine. These early increases in NGAL concentration had a much greater risk of adverse medical outcomes than patients who tested negative for NGAL. NGAL positive patients were 16 times more likely to need dialysis, three times more likely to die during hospitalization, and on average, they spent three extra days in intensive care and eight extra days in the hospital.

Prasad Devarajan, MD, is one of the lead authors of the study, and a departmental director at Cincinnati Children's Hospital Medical Center, (Cincinnati, OH, USA). He said, "This study describes a new biomarker (NGAL) that completely outperforms the current serum creatinine-based criteria for the early detection of AKI and its devastating clinical outcomes. We concluded that a substantial numbers of patients might reasonably be classified as having subclinical AKI, even though they do not fulfill current creatinine-based criteria for AKI." The researchers now plan to pursue a prospective multicenter study to further verify the effectiveness of the NGAL test as a prognostic biomarker in a large population of patients in critical care settings. The study was published on April 26, 2011, in the Journal of the American College of Cardiology (JACC).

Related Links:

Cincinnati Children's Hospital Medical Center


Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Manual Pipetting Aid
Pipette Controllers macro
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The study compares rapid molecular CPE diagnostics, which can return results in about one hour, with culture-based screening, which typically takes about 48 hours (Image credit: Adobe Stock)

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

Pathology

view channel
Image: The VENTANA PTEN (SP218) RxDx Assay is a qualitative IHC assay for assessing PTEN protein in prostate adenocarcinoma, with staining performed using the OptiView DAB IHC Detection Kit on a BenchMark ULTRA instrument (Photo courtesy of Roche)

New Companion Diagnostic Expands Precision Medicine in Prostate Cancer

Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.